濮阳市东方医院价格非常低濮阳东方妇科医院网上咨询,濮阳东方男科医院口碑非常好,濮阳东方医院妇科做人流收费非常低,濮阳东方男科非常靠谱,濮阳东方男科医院网上挂号,濮阳东方医院治阳痿口碑很好,濮阳东方医院看妇科病收费便宜

The Trump administration is extending a ban on green cards issued outside the United States until the end of the year and adding many temporary work visas to the freeze, including those used heavily by technology companies and multinational corporations. The administration is casting the effort as a way to free up jobs in an economy reeling from the coronavirus. A senior official who spoke to reporters on condition of anonymity estimated the restrictions will free up to 525,000 jobs for Americans. Through the first 60 days of the program, the senior administration official said the White House projects that the visa ban saved around 50,000 American jobs, but could not specify the type of jobs. The ban does not impact refugees or people already in the United States, a senior official said. The ban, while temporary, would amount to major restructuring of legal immigration if made permanent. 909

The United Nations Security Council unanimously approved a 30-day ceasefire resolution in Syria after a relentless bombardment of the country's eastern Ghouta enclave near Damascus that has left hundreds dead.Saturday's vote, which was supposed to be at noon, was held up by deliberations for two hours and comes after several days of delay.In a speech following the vote, US Ambassador to the UN Nikki Haley argued that the council is "late to respond to this crisis. Very late."More than 400 people have been killed since Sunday in bombing raids in eastern Ghouta.Around 400,000 people are in hiding as the rebel-held suburb crumbles around them after being pounded with shells, mortars and bombs dropped by Russian-backed Syrian regime forces since Sunday night.The-CNN-Wire? & ? 2018 Cable News Network, Inc., a Time Warner Company. All rights reserved. 869

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The South Carolina Education Lottery reported on its website early Wednesday morning that one winning ticket was sold in its state.Mega Millions announced the win in a statement early Wednesday."The moment we've been waiting for finally arrived, and we couldn't be more excited," said Gordon Medenica, lead director of the Mega Millions Group and Director of Maryland Lottery and Gaming. "This is truly a historic occasion. We're so happy for the winner, and we know the South Carolina Education Lottery can't wait to meet the lucky ticket holder."The Mega Millions jackpot on Tuesday reached .573 billion, the game's largest-ever grand prize but not quite the nation's biggest prize of all time. A Powerball prize in 2016 was for .586 billion. The winning numbers on Tuesday were:28-70-5-62-65 and the Mega Ball was 5.Had a winning ticket not been sold on Tuesday, Friday's jackpot would have reached billion. Winning Tuesday's entire jackpot means either taking the .6 billion winnings in annuity payments spread over 29 years, or taking the lump sum of 3 million.  1112

The White House privately warned the mayors of 11 major U.S. cities on Wednesday that they need to take "aggressive" steps to control COVID-19 outbreaks, the Center for Public Integrity reports.The warning came from Dr. Deborah Birx, the response coordinator for the White House Coronavirus Task Force. In the call, which the Center for Public Integrity included "hundreds of emergency managers and other state and local leaders," she identified 11 cities that are seeing an increase in the percentage of positive COVID-19 tests they've taken in recent weeks. Those cities were Baltimore, Cleveland, Columbus, Indianapolis, Las Vegas, Miami, Minneapolis, Nashville, New Orleans, Pittsburgh and St. Louis.“When you first see that increase in test positivity, that is when to start the mitigation efforts,” she said in a recording obtained by Public Integrity. “I know it may look small and you may say, ‘That only went from 5 to 5-and-a-half [percent], and we’re gonna wait and see what happens.’ If you wait another three or four or even five days, you’ll start to see a dramatic increase in cases.”The Center for Public Integrity also published a seven-minute segment of the conference call.Public Integrity · Dr. Deborah Birx CallIt's unclear who provided the Center for Public Integrity with the recording, which was closed to the press. The outlet also reported that it's unclear which local governments were on the call, which was hosted by the White House Office of Intergovernmental Affairs. Officials in Cleveland told the outlet that they were not on the call.Birx's call came the day after President Donald Trump resumed his daily coronavirus briefings. During those briefings, Trump encouraged the nations to wear a mask when in public — a significant shift after he refused to do so in public appearances earlier this year. But Trump also seemed to downplay the severity of the virus by claiming that mortality is falling, despite figures from Johns Hopkins that show mortality increasing. 2009